Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Digestive SystemDRG 382-complicated-peptic-ulcer-without-cc-mcc
    Ask Trek AI about this page

    Complicated Peptic Ulcer without CC/MCC: Inpatient Reimbursement Overview

    DRG 382 addresses complicated peptic ulcer disease admissions that lack Major Complication or Comorbidity and Complication or Comorbidity, focusing on local ulcer-related complications without higher-severity comorbid conditions. This classification matters for inpatient reimbursement because Diagnosis-Related Group assignment establishes the Medicare prospective payment for the hospitalization and influences hospital revenue for these surgical and medical encounters.

    Customize your policy alerts

    Sign up for drg 382 policy alerts

    Get alerted when payer policies referencing 382 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 382 Overview

    DRG 382 covers inpatient admissions for complicated peptic ulcer disease without a Major Complication or Comorbidity and without a Complication or Comorbidity. This includes cases with local complications such as hemorrhage or perforation that do not meet coding criteria for higher-severity payment adjustments. It matters for Medicare payment because the Diagnosis-Related Group assignment drives the fixed prospective payment amount for the hospital stay. Accurate coding of associated procedures and comorbid conditions determines whether the case remains in DRG 382 or shifts to a higher-paying Diagnosis-Related Group.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials of acute endoscopic and minimally invasive interventions for bleeding or perforated peptic ulcers: randomized or cohort studies comparing timing and techniques of endoscopic hemostasis, use of interventional radiology embolization, and surgical approaches in patients hospitalized with complicated peptic ulcer disease (active GI bleeding, perforation, or gastric outlet obstruction). The patient population includes adults admitted emergently with complications requiring urgent procedures; outcomes assess hemostasis success, rebleeding rates, need for salvage surgery, length of stay, and in-hospital mortality. This research is important to clinicians and payers because it informs which acute interventions reduce resource use, complications, and costly prolonged hospitalizations in the inpatient episode covered by this DRG.
    • Comparative effectiveness studies of peri-procedural medical management strategies in hospitalized patients without major comorbid complications: pragmatic trials or observational comparative-effectiveness research evaluating proton pump inhibitor dosing strategies, eradication therapy timing for Helicobacter pylori when applicable, and transfusion thresholds in patients admitted for complicated peptic ulcer but without CC/MCC. The focus population is patients with modifiable medical management variables during the index admission who are at moderate risk for rebleeding but do not have major coexisting illnesses; endpoints include rebleeding, readmission within 30 days, transfusion requirements, and inpatient costs. Results guide hospital protocols and payer policy around standardized care bundles that may shorten stays and reduce variation in resource utilization for this DRG cohort.
    • Post-discharge outcomes and care-transition studies examining readmission prevention, outpatient follow-up, and long-term ulcer recurrence: cohort studies or interventional trials testing structured discharge pathways, patient education, outpatient endoscopy scheduling, adherence support for eradication therapy, and coordination with primary care for NSAID deprescribing. The study population is survivors of an index hospitalization for complicated peptic ulcer without major complications, monitored for 30- to 180-day outcomes including readmissions, recurrent bleeding, medication adherence, and outpatient resource use. These studies are relevant because reducing post-discharge events and readmissions directly impacts total episode costs and quality metrics that matter to both providers and payers managing care under this DRG.

    Related Codes

    326-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-MCC

    Stomach, Esophageal and Duodenal Procedures with MCC: Inpatient Reimbursement Overview

    327-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-CC

    Stomach, Esophageal and Duodenal Procedures with CC: Inpatient Reimbursement Overview

    328-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITHOUT-CC-MCC

    Stomach, Esophageal and Duodenal Procedures without CC/MCC: Inpatient Reimbursement Overview

    329-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

    Major Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

    330-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-CC

    Major Small and Large Bowel Procedures with CC: Inpatient Reimbursement Overview

    331-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITHOUT-CC-MCC

    Major Small and Large Bowel Procedures without CC/MCC: Inpatient Reimbursement Overview

    332-RECTAL-RESECTION-WITH-MCC

    Rectal Resection with MCC: Inpatient Reimbursement Overview

    333-RECTAL-RESECTION-WITH-CC

    Rectal Resection with CC: Inpatient Reimbursement Overview

    334-RECTAL-RESECTION-WITHOUT-CC-MCC

    Rectal Resection without CC/MCC: Inpatient Reimbursement Overview

    335-PERITONEAL-ADHESIOLYSIS-WITH-MCC

    Peritoneal Adhesiolysis with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 57

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.